Hebang Biotech released its 2026 interim report, with net profit attributable to the parent company of 380 million yuan, up 634.30% from the same period last year. Total operating revenue was 2.888 billion yuan, a decrease of 1.033 billion yuan from the same reporting period last year, down 26.34% year-on-year. Net cash inflow from operating activities was 189 million yuan, up 29.98% year-on-year, achieving two consecutive years of growth. The company's latest asset-liability ratio was 34.74%, down 1.96 percentage points from the previous quarter; the latest gross margin was 28.87%, up 4.50 percentage points from the previous quarter, achieving four consecutive quarters of growth.
Sichuan Hebang Biotechnology Co LtdNet profit up 634.30% year-on-year, though revenue declined.